ALKS

Alkermes plc (NASDAQ:ALKS) is an Irish-domiciled biopharmaceutical company founded in 1987 and publicly traded since 1991. Originally established as a drug delivery technology company, Alkermes has evolved into a pure-play neuroscience-focused biopharmaceutical enterprise following the planned separation of its oncology business in recent years. The company researches, develops, and commercializes pharmaceutical products primarily targeting central nervous system disorders, with a particular emphasis on schizophrenia, bipolar disorder, alcohol dependence, and opioid dependence. Headquartered in Dublin, Ireland, with significant operations in the United States, Alkermes has built a substantial commercial presence in the psychiatric and addiction medicine markets through both proprietary products and manufacturing partnerships with major pharmaceutical companies.